Novartis International AG has reached agreement to sell its influenza vaccines business to CSL Ltd of Australia for US $275 million, subject to regulatory approvals. The transaction is expected to close in the second half of 2015. ---Subscribe to MedNous to access this article--- Finance, Grants, Deals Company News
